Chinese drugmaker receives FDA warning letter after management hindered inspectionnews2024-11-19T19:37:21+00:00November 19th, 2024|Endpoints News|
Syndax’s Revuforj wins FDA approval in aggressive form of leukemianews2024-11-18T19:37:56+00:00November 18th, 2024|Endpoints News|
FDA offers more guidance on developing cell and gene therapiesnews2024-11-18T19:21:10+00:00November 18th, 2024|Endpoints News|
What is the future of the Trump administration’s pharmaceutical policies?news2024-11-15T19:08:08+00:00November 15th, 2024|Endpoints News|
Lilly sues US government over proposed 340B rebate modelnews2024-11-15T04:12:18+00:00November 15th, 2024|Endpoints News|
President-elect Trump selects Robert F. Kennedy Jr. to lead HHSnews2024-11-14T21:06:43+00:00November 14th, 2024|Endpoints News|
European drug regulator reverses opinion on Eisai and Biogen’s Alzheimer’s drugnews2024-11-14T20:11:55+00:00November 14th, 2024|Endpoints News|
FDA approves PTC’s ultra-rare disease gene therapynews2024-11-14T05:11:24+00:00November 14th, 2024|Endpoints News|
FDA drug inspections have fallen from 2016 peak, GAO saysnews2024-11-13T18:19:08+00:00November 13th, 2024|Endpoints News|
FDA denies Ocaliva full approval, but Intercept hopes to keep drug on marketnews2024-11-12T19:14:56+00:00November 12th, 2024|Endpoints News|
